374809-97-9

Upstream product

• 10533-22-9 1-(1,2,4,5-tetrahydro-benzo[d]azepin-3-yl)-ethanone 
• 6652-06-8 4-(4-chlorophenyl)-1,2,3,6-tetrahydropiperidine hydrochloride 
• 4424-20-8 2,3,4,5-tetrahydro-1H-3-benzazepine 

Downstream Products

• 1345688-43-8 4-[4-(4-chlorophenyl)piperidin-1-yl]-1-(3-propionyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)butan-1-one 
• 1345688-44-9 1-(3-butyryl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-[4-(4-chlorophenyl)piperidin-1-yl]butan-1-one 
• 1345688-45-0 4-[4-(4-chlorophenyl)piperidin-1-yl]-1-[3-(cyclopropylcarbonyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]butan-1-one 
• 1345688-46-1 4-[4-(4-chlorophenyl)piperidin-1-yl]-1-(3-pentanoyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)butan-1-one 
• 1345688-47-2 1-(3-benzoyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-[4-(4-chlorophenyl)piperidin-1-yl]butan-1-one 
• 1345688-48-3 4-[4-(4-chlorophenyl)piperidin-1-yl]-1-[3-(methylsulfonyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]butan-1-one 
• 1345688-49-4 4-[4-(4-chlorophenyl)piperidin-1-yl]-1-[3-(ethylsulfonyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]butan-1-one 
• 1345688-69-8 methyl-7-{4-[4-(4-chlorophenyl)piperidin-1-yl]butanoyl}-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate hydrochloride 
• 1345688-51-8 7-{4-[4-(4-chlorophenyl)piperidin-1-yl]butanoyl}-N-ethyl-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxamide 
• 757179-41-2 4-[4-(4-chlorophenyl)piperidin-1-yl]-1-(3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-butan-1-one 
• 374812-87-0 1-(3-acetyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-[4-(4-chlorophenyl)-1-piperidinyl]-1-butanol 
• 374809-98-0 4-[4-(4-chlorophenyl)-1-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-butanone 

Relevant academic research and scientific papers

Melanin-concentrating hormone receptor 1 antagonists: Synthesis, structure-activity relationship, docking studies, and biological evaluation of 2,3,4,5-tetrahydro-1H-3-benzazepine derivatives

Melanin-concentrating hormone receptor 1 (MCHR1) antagonists have been studied as potential agents for the treatment of obesity. Initial structure-activity relationship studies of in-house hit compound 1a and subsequent optimization studies resulted in th